Up next

Autoplay

Daratumumab effects significant responses in highly refractory multiple myeloma patients

5 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Saad Z. Usmani, MD, FACP & Director of Clinical Research at the University of North Carolina at Chapel Hill, Levine Cancer Institute discusses clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma at the 57th American Society of Hematology Annual Meeting & Exposition.

MDLinx Conference Coverage - 57th American Society of Hematology Annual Meeting & Exposition: http://www.mdlinx.com/oncology..../conference-intervie

MDLinx: http://www.mdlinx.com/
Smartest Doc & Board Exam Prep: http://www.thesmartestdoc.com/
M3 USA: http://usa.m3.com/

Follow MDLinx:
Facebook - https://www.facebook.com/MDLinx
Twitter - https://twitter.com/MDLinx
Google+ - https://plus.google.com/+Mdlinx/

Show more
0 Comments sort Sort By

Up next

Autoplay